Doximity, Inc. (DOCS) Stock Analysis and Metrics

Sector: Healthcare Industry: Health Information Services CIK: 0001516513

Market Cap 4.41 Bn

P/E 18.51

P/S 6.91

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 9.76

Add ratio to table...

About

Doximity, Inc. operates a digital platform that connects U. S. medical professionals and provides them with tools for communication, career management, and clinical workflow. The platform is free for verified physicians, nurse practitioners, physician assistants and medical students who join to access a professional network, a personalized newsfeed, and productivity applications. Members can create a detailed professional profile, exchange secure messages, schedule on call shifts, conduct video visits, and receive curated medical news tailored to...

Doximity, Inc. operates a digital platform that connects U. S. medical professionals and provides them with tools for communication, career management, and clinical workflow. The platform is free for verified physicians, nurse practitioners, physician assistants and medical students who join to access a professional network, a personalized newsfeed, and productivity applications. Members can create a detailed professional profile, exchange secure messages, schedule on call shifts, conduct video visits, and receive curated medical news tailored to their specialties.

Doximity, Inc. generates revenue primarily through subscription fees for three solution sets offered to healthcare industry customers. The Marketing Solutions suite lets pharmaceutical manufacturers and health systems deliver sponsored content to members via the newsfeed, workflow tools, and direct messaging channels. Revenue is recognized ratably over the subscription period and customers are typically invoiced on an annual or multi year basis. The Hiring Solutions suite provides health systems and medical recruiting firms with access to the platform’s candidate database and tools for job postings, sending direct messages, and the Curative Talent staffing service. The Workflow Solutions suite offers telehealth services, on call scheduling, and AI powered clinical tools to hospitals and health systems seeking to reduce administrative burden and improve patient contact.

The company operates through the following segments.

• Marketing Solutions enables pharmaceutical manufacturers and health systems to run sponsored campaigns that place articles, videos, and other content inside members’ newsfeeds, within workflow applications, or in private messages to increase brand visibility and drive engagement. Customers can target audiences by specialty, geographic location, practice setting, and clinical interest to ensure the sponsored material reaches the most relevant physicians.

• Hiring Solutions provides health systems and medical recruiting firms with searchable access to the Doximity professional network, tools for posting jobs, sending direct messages, and the Curative Talent service that offers personalized staffing support. Recruiters can use data driven insights to identify passive candidates who are not actively seeking new roles but may be open to the right opportunity.

• Workflow Solutions delivers telehealth through Dialer Enterprise, on call scheduling via AMiON, and AI powered writing assistance such as Doximity GPT to help clinicians reduce paperwork, manage shifts, and conduct virtual patient visits. Enterprise clients receive dedicated support, usage reporting, and the ability to brand the telehealth experience to match their internal systems.

Doximity, Inc. holds a leading position as the largest dedicated online network for U. S. physicians and other medical professionals. The platform claims more than eighty percent of U. S. physicians and a majority of nurse practitioners and physician assistants among its registered members. Key competitors for member acquisition include general social networks such as LinkedIn, Facebook, Google, and X, which offer broad professional profiling but lack the specialty focus of Doximity. In the marketing solutions space, the company competes with health focused websites and apps like WebMD Medscape and various digital advertising agencies that target physician audiences. For hiring solutions, rivals consist of traditional job boards, healthcare staffing firms, and emerging digital recruiting platforms that serve the medical labor market. Regarding workflow tools, competitors include telehealth providers such as Teladoc Health and American Well, video conferencing services like Zoom Video Communications and Microsoft Teams, and scheduling applications such as QGenda. Doximity’s competitive advantages stem from its physician first design, its HIPAA compliant communication tools, the strong network effects generated by its large member base, and the proprietary data set that enables precise targeting and personalized content delivery. The network effect means that as more physicians join, the platform becomes more valuable for both members and customers, creating a self reinforcing cycle of growth. High switching costs arise because members have built extensive professional profiles, accumulated connections, and integrated the tools into their daily clinical routines.

The company’s customers are primarily pharmaceutical manufacturers that purchase marketing programs to reach physicians with information about new drugs and clinical trials. Health systems and hospitals also subscribe to marketing, hiring, and workflow solutions to support recruitment efforts, improve care coordination, and offer telehealth services to patients. Medical recruiting firms use the hiring solutions to identify passive and active candidates for locum tenens and permanent positions across specialties. Additionally, Doximity collaborates with organizations such as U. S. News & World Report to provide physician search and scheduling features that enhance the visibility of its network to prospective patients. Long term contracts with large pharmaceutical companies often include multiple brands and therapeutic areas, providing a stable base of recurring revenue. Health system clients frequently expand their usage across different service lines such as cardiology, oncology, and neurology after observing a positive return on initial investments.

Investment thesis

Bull case

Doximity’s member base surpassed 3 million, with over 85 % of U.S. physicians and two‑thirds of NPs and PAs actively registered. This penetration gives the platform a network effect that is difficult for new entrants to replicate, especially given the trust that clinicians place in a peer‑verified ecosystem. The company’s record highs in quarterly, monthly, weekly, and daily active users—particularly for news feed, workflow, and AI products—show that physicians are not only joining but also deeply engaging across multiple verticals. This high engagement rate translates into recurring subscription revenue and creates a stable foundation for future upsell opportunities.
Revenue grew 10 % year‑over‑year to $185 million, exceeding the high end of guidance and marking a 2 % beat. The 60 % adjusted EBITDA margin underscores strong operating leverage and efficient cost management, especially when compared to the 61 % margin reported a year earlier. Even with the noted gross margin decline to 91 % due to AI infrastructure investments, the company has maintained a healthy free‑cash‑flow generation of $58.5 million in the quarter, which can fund strategic initiatives without external financing. This blend of revenue growth, margin strength, and cash flow resilience positions Doximity to accelerate investment in AI while preserving shareholder value.
Net revenue retention at 112 %—and 117 % for the top 20 customers—demonstrates robust expansion within the existing customer base. The fact that 84 % of total revenue is derived from 126 customers generating at least $500,000 each shows a concentration in large accounts, but it also indicates that the platform is delivering compelling value to enterprise‑level users. A high retention rate suggests that customers are willing to pay for incremental features and that churn risk is low, which is especially important in a market where alternative solutions could erode market share. Retention also supports the company’s ability to forecast revenue with greater precision and to justify premium pricing for advanced modules.
The acquisition of Pathway.ai and its seamless integration have accelerated AI adoption, with over 300,000 unique prescribers using Docs GPT in Q3. The product’s performance—outperforming competitors in a controlled trial—serves as a credible proof point that can drive additional adoption across health systems. By embedding AI into core workflows (e.g., telehealth visits, fax summarization), Doximity ensures that physicians interact with AI organically, increasing usage frequency and data capture for model refinement. This high adoption volume also signals that the forthcoming commercial AI products will likely hit the market with a pre‑existing, highly engaged user base, reducing time‑to‑revenue for future monetization.
Doximity Dialer has held the top spot among health‑system CIOs for five consecutive years, outperforming major competitors such as Microsoft Teams and Zoom. This dominance in a critical telehealth segment creates a strong moat, as CIOs increasingly prefer a single, integrated platform that can handle scheduling, video, fax, and AI. The platform’s unique integration with telephony providers ensures high call‑through rates and low spam flags, which enhances the user experience and cements institutional trust. Moreover, the continued leadership in this space signals that the company can leverage its position to cross‑sell additional modules and expand into new revenue streams.

Doximity’s member base surpassed 3 million, with over 85 % of U.S. physicians and two‑thirds of NPs and PAs actively registered. This penetration gives the platform a network effect that is difficult for new entrants to replicate, especially given the trust that clinicians place in a peer‑verified ecosystem. The company’s record highs in quarterly, monthly, weekly, and daily active users—particularly for news feed, workflow, and AI products—show that physicians are not only joining but also deeply engaging across multiple verticals. This high engagement rate translates into recurring subscription revenue and creates a stable foundation for future upsell opportunities.
Revenue grew 10 % year‑over‑year to $185 million, exceeding the high end of guidance and marking a 2 % beat. The 60 % adjusted EBITDA margin underscores strong operating leverage and efficient cost management, especially when compared to the 61 % margin reported a year earlier. Even with the noted gross margin decline to 91 % due to AI infrastructure investments, the company has maintained a healthy free‑cash‑flow generation of $58.5 million in the quarter, which can fund strategic initiatives without external financing. This blend of revenue growth, margin strength, and cash flow resilience positions Doximity to accelerate investment in AI while preserving shareholder value.
Net revenue retention at 112 %—and 117 % for the top 20 customers—demonstrates robust expansion within the existing customer base. The fact that 84 % of total revenue is derived from 126 customers generating at least $500,000 each shows a concentration in large accounts, but it also indicates that the platform is delivering compelling value to enterprise‑level users. A high retention rate suggests that customers are willing to pay for incremental features and that churn risk is low, which is especially important in a market where alternative solutions could erode market share. Retention also supports the company’s ability to forecast revenue with greater precision and to justify premium pricing for advanced modules.
The acquisition of Pathway.ai and its seamless integration have accelerated AI adoption, with over 300,000 unique prescribers using Docs GPT in Q3. The product’s performance—outperforming competitors in a controlled trial—serves as a credible proof point that can drive additional adoption across health systems. By embedding AI into core workflows (e.g., telehealth visits, fax summarization), Doximity ensures that physicians interact with AI organically, increasing usage frequency and data capture for model refinement. This high adoption volume also signals that the forthcoming commercial AI products will likely hit the market with a pre‑existing, highly engaged user base, reducing time‑to‑revenue for future monetization.
Doximity Dialer has held the top spot among health‑system CIOs for five consecutive years, outperforming major competitors such as Microsoft Teams and Zoom. This dominance in a critical telehealth segment creates a strong moat, as CIOs increasingly prefer a single, integrated platform that can handle scheduling, video, fax, and AI. The platform’s unique integration with telephony providers ensures high call‑through rates and low spam flags, which enhances the user experience and cements institutional trust. Moreover, the continued leadership in this space signals that the company can leverage its position to cross‑sell additional modules and expand into new revenue streams.

Bear case

The company’s revenue concentration—84 % from 126 customers generating at least $500,000 each—creates a significant risk of churn or reduced spend from a few large accounts. Any contractual renegotiation or loss of a top 20 customer could materially erode revenue and margin, given the current retention focus on high‑ticket clients. This concentration is especially vulnerable in a market experiencing policy uncertainty, where budgetary constraints may prompt customers to seek cheaper alternatives or to delay platform expansion. Diversifying the customer base is critical to mitigate this risk but may require additional marketing spend that could compress margins.
Policy uncertainty surrounding MFN agreements and other pharma‑industry budgetary mechanisms has already delayed bookings and pushed revenue into Q4. The company’s guidance maintains a flat full‑year outlook despite Q3 outperformance, reflecting the potential for sustained headwinds from these policy delays. If similar or new regulatory changes arise, the company could face further booking deferrals or reduced demand for advertising and AI modules. This uncertainty makes it difficult for management to project revenue growth accurately and could lead to earnings volatility that may alarm investors.
AI infrastructure investments have already pulled the non‑GAAP gross margin from 93 % to 91 %, indicating a cost escalation that may continue as AI adoption scales. While the company plans to monetize AI later in the year, the current lack of revenue from AI products exacerbates the margin pressure, especially if the rollout is delayed or if adoption is slower than anticipated. Additional AI spending without immediate revenue can erode cash flow and limit the firm’s capacity to invest in other growth levers, such as paid search or new product development.
Management’s emphasis on “AI safety” and the reference to a 22 % clinical harm rate from recent studies highlight an industry‑wide risk that could slow AI adoption. Even with a peer‑review system, the potential for misdiagnosis or erroneous recommendations poses a significant liability risk that could prompt regulatory scrutiny. Hospitals may impose stricter controls or opt for alternative AI solutions with lower perceived risk, which could limit Doximity’s ability to capture AI market share. The company’s current strategy relies heavily on trust, but the pace of regulatory development could outstrip its capacity to adapt quickly.
The CFO’s medical leave and the interim oversight by the audit committee chair introduce an element of uncertainty in financial governance and reporting. While the company has not disclosed any material financial irregularities, the absence of a dedicated CFO may affect the timeliness and depth of financial analysis, potentially impacting investor confidence. A prolonged CFO absence could also delay critical decisions on capital allocation, such as the timing of AI product launches or share‑repurchase programs, which could influence market perception of the company’s strategic direction.

The company’s revenue concentration—84 % from 126 customers generating at least $500,000 each—creates a significant risk of churn or reduced spend from a few large accounts. Any contractual renegotiation or loss of a top 20 customer could materially erode revenue and margin, given the current retention focus on high‑ticket clients. This concentration is especially vulnerable in a market experiencing policy uncertainty, where budgetary constraints may prompt customers to seek cheaper alternatives or to delay platform expansion. Diversifying the customer base is critical to mitigate this risk but may require additional marketing spend that could compress margins.
Policy uncertainty surrounding MFN agreements and other pharma‑industry budgetary mechanisms has already delayed bookings and pushed revenue into Q4. The company’s guidance maintains a flat full‑year outlook despite Q3 outperformance, reflecting the potential for sustained headwinds from these policy delays. If similar or new regulatory changes arise, the company could face further booking deferrals or reduced demand for advertising and AI modules. This uncertainty makes it difficult for management to project revenue growth accurately and could lead to earnings volatility that may alarm investors.
AI infrastructure investments have already pulled the non‑GAAP gross margin from 93 % to 91 %, indicating a cost escalation that may continue as AI adoption scales. While the company plans to monetize AI later in the year, the current lack of revenue from AI products exacerbates the margin pressure, especially if the rollout is delayed or if adoption is slower than anticipated. Additional AI spending without immediate revenue can erode cash flow and limit the firm’s capacity to invest in other growth levers, such as paid search or new product development.
Management’s emphasis on “AI safety” and the reference to a 22 % clinical harm rate from recent studies highlight an industry‑wide risk that could slow AI adoption. Even with a peer‑review system, the potential for misdiagnosis or erroneous recommendations poses a significant liability risk that could prompt regulatory scrutiny. Hospitals may impose stricter controls or opt for alternative AI solutions with lower perceived risk, which could limit Doximity’s ability to capture AI market share. The company’s current strategy relies heavily on trust, but the pace of regulatory development could outstrip its capacity to adapt quickly.
The CFO’s medical leave and the interim oversight by the audit committee chair introduce an element of uncertainty in financial governance and reporting. While the company has not disclosed any material financial irregularities, the absence of a dedicated CFO may affect the timeliness and depth of financial analysis, potentially impacting investor confidence. A prolonged CFO absence could also delay critical decisions on capital allocation, such as the timing of AI product launches or share‑repurchase programs, which could influence market perception of the company’s strategic direction.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	28.30 Bn	14.85	1.35	10.13 Bn
2	VEEV	Veeva Systems Inc	25.58 Bn	28.11	8.01	-
3	BTSG	BrightSpring Health Services, Inc.	11.57 Bn	54.88	0.85	2.50 Bn
4	HQY	Healthequity, Inc.	7.08 Bn	33.00	5.39	0.96 Bn
5	DOCS	Doximity, Inc.	4.41 Bn	18.51	6.91	-
6	WAY	Waystar Holding Corp.	3.58 Bn	26.69	3.10	1.47 Bn
7	HNGE	Hinge Health, Inc.	2.95 Bn	-6.00	5.07	-
8	PRVA	Privia Health Group, Inc.	2.76 Bn	118.95	1.30	-

Research Tools

Doximity, Inc. (NYSE: DOCS)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Doximity, Inc. (NYSE: DOCS)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password